

Client Information

Required Information

Account #: _____ **Account Name:** _____
Street Address: _____

City, ST, ZIP: _____
Phone: _____ **Fax:** _____
 Additional Reporting Fax: _____
 Requisition Completed by: _____ Date: _____
Ordering Physician (please print: Last, First): _____ **NPI #:** _____
Treating Physician (please print: Last, First): _____ **NPI #:** _____
 The undersigned certifies that he/she is licensed to order the test(s) listed below and that such test(s) are medically necessary for the care/treatment of this patient.
Authorized Signature: _____ **Date:** _____

Patient Information

Last Name: _____ Male Female
First Name: _____ **M.I.** _____ Other Pt ID/Acct #: _____
Date of Birth: mm _____ / dd _____ / yyyy _____ Medical Record #: _____
 Client represents it has obtained informed consent from patient to perform the services described herein.

3rd Party Specimen Location

ONCOLOGY OFFICE TO COMPLETE
Client Services will request specimen from Pathology site.

Pathology Site: _____
Address: _____
Phone: _____ **Fax:** _____
Body Site: _____

Billing Information

Required: Please include face sheet and front/back of patient's primary and secondary insurance cards.

Patient Status (Must Choose 1): **Bill to:** Client Bill Insurance/Medicaid
 Hospital Patient (in) Medicare Patient/Self-Pay
 Hospital Patient (out) Bill charges to other Hospital/Facility:
 Non-Hospital Patient _____
 Prior Authorization # _____ See the NeoGenomics.com Billing section for more info.

Clinical Information

Required: Please attach patient's pathology report (required), clinical history, and other applicable report(s).

ICD-10 (Diagnosis) Code/Narrative (Required): _____
 Reason for Referral: _____
 New Diagnosis Relapse In Remission Monitoring
 Staging: 0 I II III IIIA IIIB IV Note: _____

Specimen Information

ONCOLOGY OFFICE & PATHOLOGY TO COMPLETE
Oncology office to complete Specimen ID and Collection Date when possible.

Specimen ID: _____ **Block ID:** _____
 Fixative/Preservative: _____ **Retrieved Date:** mm _____ / dd _____ / yyyy _____
Hospital Discharge Date: mm _____ / dd _____ / yyyy _____
Collection Date: mm _____ / dd _____ / yyyy _____ **Collection Time:** _____ AM PM
 Primary Metastasis – If Metastasis, list Primary: _____
 Slides # _____ Unstained _____ Stained _____ H&E _____
 Paraffin Block(s) #: _____ **Choose best block** (for global molecular/NGS testing only).
 Submit ≤4 FFPE blocks. Blocks will be combined for molecular testing when necessary.
 Peripheral Blood #: _____ *For all other testing, specify which block to use for each if sending multiple blocks. See back for details.*

Breast Marker & Gastric/GEA HER2 Fixation (CAP/ASCO Requirement)

Cold ischemic time ≤ 1 hour: Yes No Unknown
 10% neutral buffered formalin: Yes No Unknown
 HER2/ER/PgR Fixation duration 6 to 72 hours: Yes No Unknown

NeoTYPE® Cancer Profiles

See reverse side for HER2 reflex information
 *Reflex to NTRK 1-3 FISH Panel instead of NTRK NGS if Pan-TRK IHC is positive or equivocal

Broad-Reach Profiles

Discovery Profile (320+ genes)*
 Primary Tumor: Breast Lung Other
 Precision Profile (70+ genes)*

Targeted Profiles

Breast Tumor Profile* HRD+ Profile
 Cervical Tumor Profile* Liposarcoma Fusion Profile
 Cholangiocarcinoma Profile Liver/ Biliary Tumor Profile*
 Colorectal Tumor Profile* Melanoma Profile*
 Endometrial Tumor Profile* Other Solid Tumor Profile*
 Esophageal Tumor Profile* Ovarian Tumor Profile*
 Gastric Tumor Profile* Pancreas Tumor Profile*
 GI Predictive Profile* Thyroid Profile*
 GIST & Soft Tissue Profile

Please contact Client Services for Brain, Head & Neck, and Lung options.

RNA-Based NGS Fusion Panels

Brain NGS Fusion Panel
 Breast NGS Fusion Panel
 Cholangio/Pancreatic NGS Fusion Panel
 Colorectal NGS Fusion Panel
 Ewing Sarcoma NGS Fusion Panel
 Lung NGS Fusion Panel (Complete, 8 genes)
 Non-Ewing Sarcoma NGS Fusion Panel
 NTRK NGS Fusion Panel
 NTRK & RET NGS Fusion Panel
 Prostate NGS Fusion Panel
 Rhabdomyosarcoma NGS Fusion Panel
 Salivary Gland NGS Fusion Panel
 Sarcoma Comprehensive NGS Fusion Panel
 Targeted Solid Tumor NGS Fusion Panel
 Thyroid NGS Fusion Panel
 Universal Solid Tumor NGS Fusion Panel

Other Testing

BRCA1/2 Mutation Analysis for Tumors
 CancerTYPE ID® with reflex to NeoTYPE Cancer Profile based on CancerTYPE ID result
 • Tumor of uncertain origin classification followed by targeted biomarkers
 • To order CancerTYPE ID™ as a stand-alone test, visit www.cancertypeid.com
 Oncomine Dx™ Target Test (for NSCLC)
 Prosigna® Assay (for breast cancer)
Prognostic risk of distant recurrence
 Patient and specimen must meet following criteria.
 Check all that apply (required):
 Post-menopausal female
 ER+ PgR+ (one or both must be positive)
 Stage and lymph node status (choose one):
 I or II with 0 positive nodes
 II with 1-3 positive nodes (≥4 nodes ineligible)
 Tumor type (choose one):
 Invasive ductal
 Invasive lobular
 Invasive ductal & lobular
 Invasive carcinoma, NOS (not otherwise specified)
 Pathology report is attached (required)
 Gross tumor size: ≤2cm >2cm
 RAS/RAF Panel

Breast Cancer Index® (BCI): separate requisition required, see website.

Specimen Requirements

Refrigerate specimen if not shipping immediately and use cool pack during transport. Please call Client Services Team with any questions regarding specimen requirements or shipping instructions at 866.776.5907 option 3. Please refer to the website for specific details on each specimen.

Additional Billing Information

Any organization referring specimens for testing services pursuant to this Requisition Form ("Client") expressly agrees to the following terms and conditions.

- 1. Binding Service Order.** This Requisition Form is a legally binding order for the services ordered hereunder ("Services") and Client agrees that it is financially responsible for all tests billable to Client hereunder.
- 2. Third Party Billing by NeoGenomics and Right to Bill Client.** Client agrees to accurately indicate on the front of the Requisition Form that either Client should be billed (e.g., Client receives reimbursement pursuant to a non-fee-for-service basis, including, but not limited to, a capitated, diagnostic related group ("DRG"), per diem, all-inclusive, or other such bundled or consolidated billing arrangement) or NeoGenomics should bill the applicable federal, state or commercial health insurer or other third party payer (collectively, "Payers") for all Services ordered pursuant to this Requisition Form. For all such Services billable to Payers, Client agrees to provide all billing information necessary for NeoGenomics to bill such payer. In the event NeoGenomics: (i) does not receive the billing information required for it to bill any Payers within ten days of the date that any Services are reported by NeoGenomics; (ii) the Services were performed for patients who have no Payer coverage arrangements; or (iii) the Payer identified by Client denies financial responsibility for the Services and indicates that Client is financially responsible, NeoGenomics shall have the right to bill such Services to Client.

Additional Specimen Information

If submitting multiple blocks, client must indicate either "Choose best block (global molecular/NGS testing only)" or assign the selection of blocks to individual tests. If multiple blocks are sent without a selection, they will be held until clarification is provided. Please call Client Services Team with any questions regarding specimen information.

Test Descriptions

Please see complete test descriptions and all available tests at our website, www.neogenomics.com.

Test Notations

Specimen Usage

NeoGenomics makes every effort to preserve and not exhaust tissue, but in small and thin specimens, there is a possibility of exhausting the specimen in order to ensure adequate material and reliable results.

NeoTYPE HER2 Reflex Default Pathways for Multimethod Profiles

Inquire for other reflex pathway options.

Colorectal, GI Predictive	Reflex to HER2 Colorectal FISH if HER2 IHC is 3+ in 11-49% and/or 2+ in $\geq 50\%$ of cells
Discovery, Endometrial, Ovarian, Pancreas	Reflex to HER2 (Other) w/Breast Scoring FISH if HER2 IHC is 2+
Other NeoTYPE Profiles	HER2 not included; does not apply

Breast Cancer Index® (BCI)

For use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breastcancer, who are distant recurrence-free. Breast Cancer Index will be performed, reported and billed separately by Biotheranostics, Inc. For comprehensive details about Breast Cancer Index including test description, intended use and limitations, and Medicare Local Coverage Determination (LCD) criteria visit www.breastcancerindex.com.

CancerTYPE ID® with reflex to NeoTYPE® Cancer Profile

The specific NeoTYPE Cancer Profile added is determined by the CancerTYPE ID result. See www.neogenomics.com for test details.

CancerTYPE ID will be performed, reported and billed separately by Biotheranostics, Inc. For comprehensive details about CancerTYPE ID including test description, intended use, and limitations, visit www.cancertypeid.com.

For our complete test menu, TAT, specimen requirements and more, please visit: www.neogenomics.com